BioCardia Announces Pricing of $10 Million Public Offering
June 17, 2020 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative...
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
May 15, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported...
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
May 05, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval
April 30, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
April 28, 2020 15:08 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia Inc.
April 14, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
April 09, 2020 14:03 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
March 31, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL
March 12, 2020 08:00 ET
|
BioCardia, Inc.
Company to Host a Conference Call with National Co-Principal Investigators on March 31, 2020 at 4:15 p.m. ET Fourth Quarter 2019 Financial Results to be Issued March 30, 2020 SAN CARLOS, Calif.,...
Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter
January 14, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...